Hong Kong / Shanghai | December 30, 2025 — HUTCHMED announced that China’s drug regulator has accepted the New Drug Application (NDA) for Savolitinib and granted it Priority Review status for the treatment of locally advanced or metastatic gastric and gastroesophageal junction cancer patients with MET amplification, marking a major regulatory milestone in precision oncology.
Science Significance
The acceptance of the NDA underscores the scientific validation of targeting MET amplification in gastric cancer, a molecular subtype associated with aggressive disease and poor prognosis. Savolitinib is an oral, potent, and highly selective MET tyrosine kinase inhibitor, designed to block abnormal activation of the MET signaling pathway driven by gene amplification. The submission is supported by a Phase II registration study conducted in Chinese patients, which met its primary endpoint of objective response rate as assessed by an independent review committee. These findings reinforce the role of biomarker-driven oncology therapies and highlight how precision medicine approaches are reshaping treatment paradigms in solid tumors where limited targeted options exist.
Regulatory Significance
From a regulatory perspective, the NDA acceptance with Priority Review by the National Medical Products Administration (NMPA) reflects the agency’s intent to accelerate access to innovative therapies addressing serious unmet medical needs. Savolitinib previously received Breakthrough Therapy Designation, and the current priority pathway may significantly shorten review timelines. This development demonstrates China’s evolving regulatory framework, which increasingly aligns with global best practices in expedited drug review, a key interest area for cGxP-focused stakeholders monitoring compliance, clinical data robustness, and regulatory convergence.
Business Significance
Advertisement
For HUTCHMED, the milestone strengthens its position as a commercial-stage biopharmaceutical company with a maturing oncology pipeline. Savolitinib is co-developed and commercialized with AstraZeneca and is already approved in China for other indications, providing an established manufacturing and commercialization base. Expansion into MET-amplified gastric cancer could broaden market potential and reinforce long-term revenue prospects. From an industry standpoint, the announcement signals continued investment confidence in targeted oncology assets, particularly those supported by companion diagnostics and defined patient populations, which are increasingly favored by payers and regulators alike.
Patients’ Significance
Gastric cancer remains one of the leading causes of cancer-related mortality in China, and patients with MET amplification represent a small but high-risk subgroup with limited treatment options after standard therapies fail. Savolitinib has the potential to become the first selective MET inhibitor approved in China for this population, offering a new targeted treatment avenue. If approved, the therapy could improve clinical outcomes and quality of life for patients who currently face poor prognoses, highlighting the patient-centric impact of precision oncology.
Policy Significance
At the policy level, this development aligns with China’s broader healthcare strategy to promote innovation, accelerate access to breakthrough medicines, and address high-burden cancers. The use of priority review mechanisms supports national goals of faster translation of clinical research into clinical practice. It also underscores the importance of robust clinical trial conduct and regulatory-grade data, reinforcing cGxP principles across development, manufacturing, and regulatory submission processes.
The NDA acceptance and priority review of savolitinib mark a pivotal moment for MET-targeted therapy in gastric cancer and reflect the growing maturity of China’s pharmaceutical innovation ecosystem. For regulators, industry leaders, and patients alike, the announcement highlights how science-driven regulation and precision medicine can converge to deliver meaningful advances in oncology. As the review progresses, savolitinib’s trajectory will be closely watched as a benchmark for future targeted cancer therapies in China and beyond.
Source: HUTCHMED (China) Limited press release
